PubMed Health⌕ Search

Biomedical subjects

M A Iñigo

Publications and source records attributed to M A Iñigo.

8 recordsLinked to original sources

[43 cycles of anabolic steroid treatment studied in athletes: the uses and secondary effects].

OBJECTIVE: To know the actual abuse of anabolic steroids by amateur athletes in our environment as well as actions and secondary effects resulting from such abuse. METHODS: Analytical observational study from May 1997 to November 1998. Forty-three therapy courses with anabolic steroids among 39 male athletes were studied. Diet and training were standardized for all participants. A verification was made that the test group started from a basal state. RESULTS: Duration of therapy was 6 weeks and the mean total dose was 2,928 mg. Significant differences were found in the test group regarding basal and post-therapy values for: transaminases (AST: 29.8 vs 45.0 IU/l, p < 0.001. ALT: 32.9 vs 51.4 IU/l, p < 0.01), cholesterol, HDL-cholesterol (31.4 vs 19.7 mg/dl, p < 0.01), LDL-cholesterol (145.9 vs 173.5 mg/dl, p < 0.01), LH (2.1 vs 0.2 U/l, p < 0.001), FSH (3.3 vs 0.4 U/l, p < 0.001), free testosterone (14.4 vs 34.0 pg/ml, p < 0.001), 17-beta-estradiol and arm muscular section (98.8 vs 103.7 cm2, p < 0.001). The inclusion of testosterone in therapy introduced a significant difference with respect to the use of synthetic anabolic agents alone, in total testosterone (4.5 vs 0.9 ng/ml, p < 0.001) and 17-beta-oestradiol, but neither with respect to free testosterone nor arm muscular section. An 84.6% of individuals in the problem group stated to complete two therapy courses in a year. CONCLUSIONS: The use of anabolic steroids increases the lean muscular mass. The most relevant secondary effects included: increased transaminase serum levels, change in the lipid profile and suppression of the hypothalamus-pituitary gland-gonad axis. The inclusion of testosterone did not increase the lean muscular mass.

Adult↗

[Bacteremia caused by Campylobacter jeikeium in 2 AIDS patients without neutropenia].

BACKGROUND: Bacteremia by Corynebacterium jeikeium is generally described in patients with a bone marrow transplantation and/or neutropenia. In 1991, the first case of bacteremia by C. jeikeium was described in a patient with AIDS and neutropenia. The aim of this study was to describe 2 cases of bacteremia by C. jeikeium in patients with AIDS without neutropenia. To the authors' knowledge, this presentation has not been described previously. METHODS: The bacteremia episode was related with a central venous catheter in both patients. The first patient was diagnosed of tuberculous lymphadenitis and cerebral toxoplasmosis and the second patient of disseminated tuberculosis. Both receive specific treatment for these diseases. Zidovudine was not administered. The bacteremia resolved in both cases after withdrawal of the catheter and antibiotic treatment with vancomycin. CONCLUSIONS: Bacteremia by Corynebacterium jeikeium should be considered in the differential diagnosis of febrile patients with AIDS and vascular catheters, even if granulocytopenia is not present. The isolation of C. jeikeium from blood in AIDS patients, particularly neutropenic patients, should be carefully evaluated by microbiologists and clinicians prior to discard it as a "contaminant".

AIDS-Related Opportunistic Infections↗

[Serum adenosine deaminase in human immunodeficiency virus infection. Its relationship with CD4+ lymphocytes and beta 2-microglobulin].

BACKGROUND: The activity of the deaminase adenosine enzyme (ADA) has principally been related with the functionalism and replication of the T lymphocytes. Its serum behavior and possible clinical use in infection by the human immunodeficiency virus type 1 (HIV-1) was studied. METHODS: A multicenter study in which the serum values of ADA were examined and compared with those of two reference markers (CD4+ lymphocytes and beta 2-microglobulin) in 35 presumably healthy donors used as controls, in 60 intravenous drug users (IVDU) seronegative for HIV-1, in 69 HIV-1 asymptomatic seropositive intravenous drug users (HIV-1+) and in 48 patients with AIDS. RESULTS: The serum values of ADA were as follows: control group 10.9 +/- 4.2 U/I; IVDU group 17.6 +/- 7.4 U/I; asymptomatic HIV-1+ group 32.7 +/- 10.2 U/I, AIDS group 46.2 +/- 18.2 U/I. Differences between the different groups were statistically significant in themselves and in relation to the control group. A negative correlation was observed (r = 0.47, p < 0.01) with the number of CD4+ lymphocytes and a positive correlation was found with respect to beta 2-microglobulin (r = 0.76, p < 0.001). The values of serum ADA activity in patients with AIDS and tuberculosis (47.4 +/- 17.2 U/I) were not significantly higher (p < 0.05) to those of patients with AIDS without this second infection (45.9 +/- 19.3 U/I). CONCLUSIONS: Serum deaminase adenosine may be a useful evolutive marker for human immunodeficiency virus type 1 given that its activity increases significantly in infected patients in agreement with the grade of immunodeficiency and its values correlate well with those of reference markers (CD4+ lymphocytes and beta 2-microglobulin).

Acquired Immunodeficiency Syndrome↗